Drug intelligence / Profile preview

ING-006

Development stage: Preclinical
Lead developer: Innospera Pharma
Modality: Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Oral

Overview

ING-006 is a novel, orally administered synthetic lipid drug developed as a dual GPR40 agonist and GPR84 antagonist. It exhibits potent antifibrotic activity in preclinical models of lung and liver fibrosis. The primary mechanism involves modulation of G-protein coupled receptors implicated in inflammation and fibrogenesis, making it a promising candidate for the treatment of idiopathic pulmonary fibrosis (IPF). ING-006 has demonstrated superior antifibrotic effects compared to other agents such as nintedanib in fibroblast and lung tissue models from IPF patients[1][2][4].

Targets

GPR84FFAR1 (Free fatty acid receptor 1)

Beyond the preview

Go deeper on ING-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ING-006.

Explore the full profile